1st or 5th yeast infection?1
Prescribe BREXAFEMME today
1st or 5th yeast infection?1
Prescribe BREXAFEMME today
Effective across a broad range of patients1
In a clinical setting, hallmark signs and symptoms of vaginal yeast infections are rated on a VSS scale from 0 (absent) to 3 (severe) to assess severity.1
These signs and symptoms include1:
- Erythema
- Edema
- Excoriation
- Itching
- Burning
- Irritation
94%
of patients in the clinical trials had a baseline VSS score of ≥7.2
BREXAFEMME clinical outcomes remained consistent regardless of
severity of VSS at baseline, weight, race, ethnicity, and Candida species.1
VANISH 303 and 306 were the largest Phase 3 clinical trials for acute VVC and used the most stringent definition of clinical cure of any vaginal yeast infection treatment, VSS=0, which indicates the total disappearance of all signs and symptoms in patients.1,2
Studied in patients with moderate-to-severe VSS5
of patients at baseline had a VSS score of ≥7
No signs
or symptoms
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
1718
Severe signs
and symptoms
Evaluated in a wide range of patient types.
KEY INCLUSION CRITERIA
Non-pregnant postmenarchal females with a diagnosis of VVC meeting the following criteria:
- Composite VSS minimum score of ≥4 with at least 2 signs or symptoms having a score of 2 (moderate) or greater
- Positive microscopic exam with 10% KOH in a vaginal sample revealing yeast forms (hyphae/pseudohyphae) or budding yeasts
- Normal vaginal pH (≤4.5)
PRIMARY ENDPOINT
Percentage of subjects with complete clinical response (VSS score of 0) at Day 10.
ADDITIONAL ENDPOINT
Sustained resolution of VVC signs and symptoms at Day 25.
TREATMENT
Single day of BREXAFEMME 600mg (two 150 mg tabs per dose, administered 12 hours apart).
